Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Panobinostat: Preliminary Phase I data

Preliminary data from 16 evaluable patients in the first 2 cohorts

Read the full 116 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE